Review



sumf2 primary antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
      Buy from Supplier

    Structured Review

    Proteintech sumf2 primary antibody
    Correlation of <t> SUMF2 </t> expression with clinicopathological characteristics in bladder cancer
    Sumf2 Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 85/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sumf2 primary antibody/product/Proteintech
    Average 85 stars, based on 2 article reviews
    sumf2 primary antibody - by Bioz Stars, 2026-05
    85/100 stars

    Images

    1) Product Images from "Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma"

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    Journal: Discover Oncology

    doi: 10.1007/s12672-025-01859-y

    Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer
    Figure Legend Snippet: Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer

    Techniques Used: Expressing

    Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer
    Figure Legend Snippet: Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer

    Techniques Used: Expressing

    SUMF2 expression was upregulated in UTUC. A Quantification of SUMF2 expression in 74 paired UTUC specimens and significance, determined using the Student's t- test. ** P < 0.01. B Representative images of SUMF2 expression in upper tract UC (UTUC) tissues. C Kaplan–Meier survival curves for overall survival and disease-free survival in patients with UTUC according to SUMF2 protein expression
    Figure Legend Snippet: SUMF2 expression was upregulated in UTUC. A Quantification of SUMF2 expression in 74 paired UTUC specimens and significance, determined using the Student's t- test. ** P < 0.01. B Representative images of SUMF2 expression in upper tract UC (UTUC) tissues. C Kaplan–Meier survival curves for overall survival and disease-free survival in patients with UTUC according to SUMF2 protein expression

    Techniques Used: Expressing

    SUMF2 knockdown inhibits migration and invasion in UC cells. A RT-qPCR analysis of SUMF2 expression in UC cancer cell lines. B RT-qPCR examination of SUMF2 expression following infection with shRNA. C The impact of SUMF2 knockdown on 5637 cell growth. D Downregulation of SUMF2 inhibited migration and invasion viabilities of 5637 cells. Data are presented as mean ± SD. **P < 0.01; *P < 0.05
    Figure Legend Snippet: SUMF2 knockdown inhibits migration and invasion in UC cells. A RT-qPCR analysis of SUMF2 expression in UC cancer cell lines. B RT-qPCR examination of SUMF2 expression following infection with shRNA. C The impact of SUMF2 knockdown on 5637 cell growth. D Downregulation of SUMF2 inhibited migration and invasion viabilities of 5637 cells. Data are presented as mean ± SD. **P < 0.01; *P < 0.05

    Techniques Used: Knockdown, Migration, Quantitative RT-PCR, Expressing, Infection, shRNA

    Correlation analysis between SUMF2 and SULF family expression in patients with BLCA. A Correlation of SUMF2 with SULF1 and SULF2 mRNA expression using TCGA datasets of BLCA (ENCORI). B Kaplan–Meier analysis of overall survival, according to SULF1 and SULF2 mRNA expression in BLCA. C Kaplan–Meier survival curves for SUMF2 and SULF1 and the SUMF2 / SULF2 axis in patients with BLCA (using TCGA data)
    Figure Legend Snippet: Correlation analysis between SUMF2 and SULF family expression in patients with BLCA. A Correlation of SUMF2 with SULF1 and SULF2 mRNA expression using TCGA datasets of BLCA (ENCORI). B Kaplan–Meier analysis of overall survival, according to SULF1 and SULF2 mRNA expression in BLCA. C Kaplan–Meier survival curves for SUMF2 and SULF1 and the SUMF2 / SULF2 axis in patients with BLCA (using TCGA data)

    Techniques Used: Expressing

    The expression of high SUMF2 / low FBXW7 axis is correlated with poor survival among patients with BLCA. A Putative binding and interaction targets of SUMF2 were identified from Pathway Commons. B Analysis of the correlation between SUMF2 and FBXW7 mRNA expression using ENCORI. C Analysis of overall survival according to FBXW7 mRNA expression (TCGA). D Kaplan–Meier analysis of overall survival among patients with BLCA by examining the combination of SUMF2 and FBXW7 mRNA expression levels. other: SUMF2 low/FBXW7 low and SUMF2 high/FBXW7 high mRNA levels
    Figure Legend Snippet: The expression of high SUMF2 / low FBXW7 axis is correlated with poor survival among patients with BLCA. A Putative binding and interaction targets of SUMF2 were identified from Pathway Commons. B Analysis of the correlation between SUMF2 and FBXW7 mRNA expression using ENCORI. C Analysis of overall survival according to FBXW7 mRNA expression (TCGA). D Kaplan–Meier analysis of overall survival among patients with BLCA by examining the combination of SUMF2 and FBXW7 mRNA expression levels. other: SUMF2 low/FBXW7 low and SUMF2 high/FBXW7 high mRNA levels

    Techniques Used: Expressing, Binding Assay

    Correlation of SUMF2 expression with clinicopathological characteristics in UTUC
    Figure Legend Snippet: Correlation of SUMF2 expression with clinicopathological characteristics in UTUC

    Techniques Used: Expressing



    Similar Products

    sumf2 primary antibody  (Proteintech)
    85
    Proteintech sumf2 primary antibody
    Correlation of <t> SUMF2 </t> expression with clinicopathological characteristics in bladder cancer
    Sumf2 Primary Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sumf2 primary antibody/product/Proteintech
    Average 85 stars, based on 1 article reviews
    sumf2 primary antibody - by Bioz Stars, 2026-05
    85/100 stars
    		  Buy from Supplier

    Image Search Results


    Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Expressing

    Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: Correlation of SUMF2 expression with clinicopathological characteristics in bladder cancer

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Expressing

    SUMF2 expression was upregulated in UTUC. A Quantification of SUMF2 expression in 74 paired UTUC specimens and significance, determined using the Student's t- test. ** P < 0.01. B Representative images of SUMF2 expression in upper tract UC (UTUC) tissues. C Kaplan–Meier survival curves for overall survival and disease-free survival in patients with UTUC according to SUMF2 protein expression

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: SUMF2 expression was upregulated in UTUC. A Quantification of SUMF2 expression in 74 paired UTUC specimens and significance, determined using the Student's t- test. ** P < 0.01. B Representative images of SUMF2 expression in upper tract UC (UTUC) tissues. C Kaplan–Meier survival curves for overall survival and disease-free survival in patients with UTUC according to SUMF2 protein expression

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Expressing

    SUMF2 knockdown inhibits migration and invasion in UC cells. A RT-qPCR analysis of SUMF2 expression in UC cancer cell lines. B RT-qPCR examination of SUMF2 expression following infection with shRNA. C The impact of SUMF2 knockdown on 5637 cell growth. D Downregulation of SUMF2 inhibited migration and invasion viabilities of 5637 cells. Data are presented as mean ± SD. **P < 0.01; *P < 0.05

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: SUMF2 knockdown inhibits migration and invasion in UC cells. A RT-qPCR analysis of SUMF2 expression in UC cancer cell lines. B RT-qPCR examination of SUMF2 expression following infection with shRNA. C The impact of SUMF2 knockdown on 5637 cell growth. D Downregulation of SUMF2 inhibited migration and invasion viabilities of 5637 cells. Data are presented as mean ± SD. **P < 0.01; *P < 0.05

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Knockdown, Migration, Quantitative RT-PCR, Expressing, Infection, shRNA

    Correlation analysis between SUMF2 and SULF family expression in patients with BLCA. A Correlation of SUMF2 with SULF1 and SULF2 mRNA expression using TCGA datasets of BLCA (ENCORI). B Kaplan–Meier analysis of overall survival, according to SULF1 and SULF2 mRNA expression in BLCA. C Kaplan–Meier survival curves for SUMF2 and SULF1 and the SUMF2 / SULF2 axis in patients with BLCA (using TCGA data)

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: Correlation analysis between SUMF2 and SULF family expression in patients with BLCA. A Correlation of SUMF2 with SULF1 and SULF2 mRNA expression using TCGA datasets of BLCA (ENCORI). B Kaplan–Meier analysis of overall survival, according to SULF1 and SULF2 mRNA expression in BLCA. C Kaplan–Meier survival curves for SUMF2 and SULF1 and the SUMF2 / SULF2 axis in patients with BLCA (using TCGA data)

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Expressing

    The expression of high SUMF2 / low FBXW7 axis is correlated with poor survival among patients with BLCA. A Putative binding and interaction targets of SUMF2 were identified from Pathway Commons. B Analysis of the correlation between SUMF2 and FBXW7 mRNA expression using ENCORI. C Analysis of overall survival according to FBXW7 mRNA expression (TCGA). D Kaplan–Meier analysis of overall survival among patients with BLCA by examining the combination of SUMF2 and FBXW7 mRNA expression levels. other: SUMF2 low/FBXW7 low and SUMF2 high/FBXW7 high mRNA levels

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: The expression of high SUMF2 / low FBXW7 axis is correlated with poor survival among patients with BLCA. A Putative binding and interaction targets of SUMF2 were identified from Pathway Commons. B Analysis of the correlation between SUMF2 and FBXW7 mRNA expression using ENCORI. C Analysis of overall survival according to FBXW7 mRNA expression (TCGA). D Kaplan–Meier analysis of overall survival among patients with BLCA by examining the combination of SUMF2 and FBXW7 mRNA expression levels. other: SUMF2 low/FBXW7 low and SUMF2 high/FBXW7 high mRNA levels

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Expressing, Binding Assay

    Correlation of SUMF2 expression with clinicopathological characteristics in UTUC

    Journal: Discover Oncology

    Article Title: Sulfatase modifying factor 2 as a predictive biomarker for urothelial carcinoma

    doi: 10.1007/s12672-025-01859-y

    Figure Lengend Snippet: Correlation of SUMF2 expression with clinicopathological characteristics in UTUC

    Article Snippet: Next, the slides were incubated with the SUMF2 primary antibody (1:100;11210-1-AP; Proteintech).

    Techniques: Expressing